MedTrace Logo

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-05-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

IRL201104

lyophilised powder for reconstitution for IV dosing

DRUG

Placebo

Matching placebo for IRL201104

Sponsors & Collaborators

  • Revolo Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Weinreich, MD, PhD · Senior Director, Revolo Biotherapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2022-10-24
Completion
2022-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05084963 on ClinicalTrials.gov